Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

Keyphrases

• Low Risk 100%
• Radiotherapy 100%
• Densification 100%
• Intermediate Prognosis 100%
• R-CHOP 100%
• Aggressive B-cell Lymphoma 100%
• R-CHOP-21 83%
• R-CHOP-14 83%
• Event-free Survival 66%
• Partial Response 50%
• Overall Survival 33%
• Age-adjusted 33%
• Progression-free Survival 33%
• Additional Treatment 33%
• International Prognostic Index 33%
• Bulky Disease 33%
• No Significant Difference 16%
• Cyclophosphamide 16%
• Intention-to-treat Analysis 16%
• Low Dose Rate 16%
• Response Rate 16%
• Doxorubicin 16%
• Phase II Trial 16%
• 2-factorial Design 16%
• Positron Emission Tomography-computed Tomography (PET-CT) 16%
• Rituximab 16%
• Response Criteria 16%
• F-18 16%
• Consolidation Radiotherapy 16%

Medicine and Dentistry

• B-Cell Lymphoma 100%
• Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine 100%
• Dose Densification 100%
• Chemotherapy 100%
• Radiation Therapy 63%
• Event Free Survival 36%
• Arm 18%
• Overall Survival 18%
• Progression Free Survival 18%
• International Prognostic Index 18%
• Diseases 18%
• Intention-to-Treat Analysis 9%
• Cyclophosphamide 9%
• Vincristine 9%
• Doxorubicin 9%
• Positron Emission Tomography-Computed Tomography 9%
• Rituximab 9%

Immunology and Microbiology

• B Cell 100%
• Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine 100%
• Dose Densification 100%
• Event Free Survival 36%
• Arm 18%
• Overall Survival 18%
• Progression Free Survival 18%
• Cyclophosphamide 9%
• Rituximab 9%
• Positron Emission Tomography-Computed Tomography 9%